Ocugen, Inc. (OCGN)
1.02
+0.02
(+2.00%)
USD |
NASDAQ |
Oct 02, 16:00
1.02
0.00 (0.00%)
After-Hours: 20:00
Ocugen EPS Diluted (Quarterly) : -0.0734 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0734 |
| March 31, 2026 | -0.0586 |
| December 31, 2025 | -0.0567 |
| September 30, 2025 | -0.066 |
| June 30, 2025 | -0.0505 |
| March 31, 2025 | -0.0526 |
| December 31, 2024 | -0.0477 |
| September 30, 2024 | -0.0466 |
| June 30, 2024 | -0.0593 |
| March 31, 2024 | -0.0464 |
| December 31, 2023 | -0.0428 |
| September 30, 2023 | -0.0457 |
| June 30, 2023 | -0.0968 |
| March 31, 2023 | -0.0768 |
| December 31, 2022 | -0.1017 |
| September 30, 2022 | -0.1012 |
| June 30, 2022 | -0.0902 |
| March 31, 2022 | -0.0876 |
| December 31, 2021 | -0.0732 |
| September 30, 2021 | -0.0541 |
| June 30, 2021 | -0.1327 |
| March 31, 2021 | -0.038 |
| December 31, 2020 | -0.0206 |
| September 30, 2020 | -0.074 |
| June 30, 2020 | -0.1934 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0749 |
| December 31, 2019 | 0.2353 |
| September 30, 2019 | -3.552 |
| June 30, 2019 | -35.00 |
| March 31, 2019 | -76.35 |
| December 31, 2018 | -1.201 |
| September 30, 2018 | -23.38 |
| June 30, 2018 | -7.718 |
| March 31, 2018 | -31.16 |
| December 31, 2017 | -15.32 |
| September 30, 2017 | -13.52 |
| June 30, 2017 | -15.00 |
| March 31, 2017 | -15.97 |
| December 31, 2016 | -38.13 |
| September 30, 2016 | -41.66 |
| June 30, 2016 | -36.60 |
| March 31, 2016 | -36.00 |
| December 31, 2015 | -37.80 |
| September 30, 2015 | -36.60 |
| June 30, 2015 | -34.80 |
| March 31, 2015 | -36.00 |
| December 31, 2014 | 102.00 |
| September 30, 2014 | -52.66 |
| June 30, 2014 | -113.22 |
| March 31, 2014 | -33.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Gilead Sciences, Inc. | -8.444 |
| MannKind Corp. | -0.0616 |
| Nektar Therapeutics | -1.229 |
| Vertex Pharmaceuticals, Inc. | 4.310 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -24.88M |
| Revenue (Quarterly) | 1.488M |
| Total Expenses (Quarterly) | 26.36M |
| Enterprise Value | 333.76M |
| Gross Profit Margin (Quarterly) | 60.62% |
| Profit Margin (Quarterly) | -1.67K% |
| Earnings Yield | -24.97% |
| Normalized Earnings Yield | -24.10 |